Major Drivers Propelling the Growth oh the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Forward: Increasing Prevalence Of Migraine Fueling The Growth Of The Market Due To Increasing Stress Levels And Improved Treatment Options
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What is the Projected CAGR for the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Size from 2025 to 2034?
The CGRP inhibitors market landscape has observed speedy growth lately and is expected to expand from $2.87 billion in 2024 to $3.17 billion in 2025, marking an impressive CAGR of 10.6%. Factors such as growing R&D investments, approval of novel drugs, higher demand for non-opioid analgesics, and a stronger emphasis on personalized medicine have contributed to this historic growth.
The market for inhibitors of the calcitonin gene-related peptide (CGRP) is projected to experience swift expansion in the upcoming years. It is forecasted to swell to $4.68 billion by 2029, with a compound annual growth rate (CAGR) of 10.2%. This surge during the forecast period is likely due to the increasing incidence of migraines, the rising implementation of migraine prevention treatments, enhanced patient awareness, and increased healthcare spending. Key trends during this forecast period will be technological progress in drug formulation, the incorporation of digital health tools, advances in precision medicine, and technological improvements in biosimilars.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The rise in migraine occurrences is projected to boost the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market in the future. Migraine, a severe headache characterized by throbbing pain typically on one side of the head and often accompanied by nausea, sensitivity to sound and light, and vomiting, is increasingly common due to heightened stress levels activating neural pathways. CGRP inhibitors are effective in managing migraines by providing a precise preventative measure which is compatible with both chronic and acute treatment plans. They help to alleviate the frequency and severity of headaches via effective CGRP receptor blockade, thereby enhancing the patient’s daily capabilities and overall well-being. As per a report by the National Library of Medicine in January 2023, the worldwide incidence of migraines is between 14% and 15%, accounting for 4.9% of the global disease load. Consequently, the escalating prevalence of migraines is fuelling the growth of the calcitonin gene-related peptide (CGRP) inhibitors market.
Which Key Market Segments Comprise the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market and Drive Its Revenue Growth?
The calcitonin gene-related peptide (CGRP) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
Which Areas Are Leading Regions in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Expansion Across the Globe?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Over the Coming Years?
Leading corporations in the calcitonin gene-related peptide (CGRP) inhibitors market are making strides in innovating new products and seeking approvals for them. Particularly, they are focusing on CGRP receptor antagonists to amplify the efficacy of migraine treatments, broaden healing indications, and deliver more accessible administration pathways, including oral and intranasal methods. CGRP receptor antagonist is a medicinal substance that inhibits the CGRP receptor, thereby impeding pain signals associated with migraines. A case in point would be the US-based biotech company, AbbVie Inc getting the approval from Food and Drug Administration (FDA) in April 2023 for their product QULIPTA (atogepant) intended for the treatment of chronic migraines in adults. QULIPTA operates by blocking the CGRP receptors, which are integral to migraine pathophysiology, thereby assisting in averting migraine episodes.
View the full report here:
How Is the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Conceptually Defined?
Calcitonin gene-related peptide (CGRP) inhibitors are a class of drugs that block the activity of the calcitonin gene-related peptide (CGRP) pathway, which is involved in transmitting pain and dilating blood vessels in the brain. These inhibitors help reduce the frequency and severity of migraines and are used as a treatment option in patients with chronic or episodic migraines.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
